Thursday’s Highlights at Noon: Clovis Oncology (CLVS), Intercept Pharma (ICPT), Veeva Systems (VEEV), Bluebird Bio (BLUE), Teva Pharmaceutical Industries (TEVA)

By Carrie Williams

So far Thursday, November 28, NASDAQ is up 0.23% and the S&P is up 0.87%. Here are this morning’s most active stocks: Clovis Oncology (CLVSResearch Report), Intercept Pharma (ICPTResearch Report), Veeva Systems (VEEVResearch Report), Bluebird Bio (BLUEResearch Report) and Teva Pharmaceutical Industries (TEVAResearch Report).

Clovis Oncology is up 12.31% in midday trading to $12.41. Shares opened today at $11.05. The company has a 52-week low of $2.93 and a 52-week high of $32.05. On the Street’s front, the average 12-month analyst price target for the stock is $11.42, marking a 3.35% potential upside from current levels. In a report issued on November 19, Evercore ISI analyst Joshua Schimmer downgraded CLVS to Hold, with a price target of $8.00, which represents a potential downside of 28% from where the stock is currently trading. Separately, on November 8, H.C. Wainwright’s Edward White reiterated a Buy rating on the stock and has a price target of $36.00.

Intercept Pharma is up 7.39% in midday trading to $109.16. Shares opened today at $101.65. The company has a 52-week low of $56.76 and a 52-week high of $131.87. On the Street’s front, the average 12-month analyst price target for the stock is $150.80, marking a 48.35% potential upside from current levels. In a report issued on November 25, Robert W. Baird analyst Brian Skorney reiterated a Buy rating on ICPT, with a price target of $227.00, which implies an upside of 123% from current levels. Separately, on the same day, Stifel Nicolaus’ Derek Archila maintained a Hold rating on the stock and has a price target of $102.00. In the last 30 days, insiders have sold $137.6K worth of ICPT shares. Over the last 3 months, the insider sentiment on Intercept Pharma has been positive based on 106 corporate insider transactions. This sentiment is slightly higher than the average sector sentiment of insiders.

Veeva Systems is down -7.17% in midday trading to $153.32. Shares opened today at $165.17. The company has a 52-week low of $79.26 and a 52-week high of $176.90. On the Street’s front, the average 12-month analyst price target for the stock is $176.44, marking a 6.82% potential upside from current levels. In a report released yesterday, Stifel Nicolaus analyst Tom Roderick maintained a Buy rating on VEEV, with a price target of $185.00, which represents a potential upside of 12% from where the stock is currently trading. Separately, on the same day, Evercore ISI’s Kirk Materne maintained a Hold rating on the stock and has a price target of $170.00. In the last 30 days, insiders purchased $8,312 worth of VEEV shares. Over the last 3 months, the insider sentiment on Veeva Systems has been negative based on 134 corporate insider transactions. This sentiment is lower than the average sector sentiment of insiders.

See today’s analyst top recommended stocks >>

Bluebird Bio is up 7% in midday trading to $80.25. Shares opened today at $75.00. The company has a 52-week low of $71.42 and a 52-week high of $163.43. On the Street’s front, the average 12-month analyst price target for the stock is $105.71, marking a 40.95% potential upside from current levels. In a report issued on November 26, Leerink analyst Mani Foroohar upgraded BLUE to Buy, with a price target of $119.00, which implies an upside of 59% from current levels. Separately, on November 19, Evercore ISI’s Joshua Schimmer downgraded the stock to Hold and has a price target of $86.00.

See today’s analyst top recommended stocks >>

Teva Pharmaceutical Industries is up 6.42% in midday trading to $10.45. Shares opened today at $9.82. The company has a 52-week low of $6.07 and a 52-week high of $24.47. On the Street’s front, the average 12-month analyst price target for the stock is $8.70, marking a -11.41% potential downside from current levels. In a report released yesterday, Gabelli & Co analyst Kevin Kedra maintained a Buy rating on TEVA. Separately, on November 20, Jefferies Co.’s David Steinberg maintained a Hold rating on the stock and has a price target of $9.00. Over the last 3 months, the insider sentiment on Teva Pharmaceutical Industries has been negative based on 50 corporate insider transactions. This sentiment is lower than the average sector sentiment of insiders.

Trending Stocks Based on Insider Activity >>